Heat Biologics submitted an investigational new drug application to the FDA for approval to test its second drug candidate, HS-410, in patients with bladder cancer. Heat announced that the HS-410 program and all of the firm's clinical trials will be supervised by Melissa Price, the company's new vice president of clinical and regulatory affairs.

Related Summaries